Monday, January 11, 2021 8:06:53 PM
Shady:
Well that is what I was asking. Don’t know the answer.
Was wondering why that old company would/could want to buy by millions of dollars of RDHL stock AT A HIGHER PRICE than Red Hill would trade at if it tanks big time. Why not just wait for it to tank and get it cheaper?
It seems like RDHL is sitting on likely positive news due out shortly (mentioned in last PR)** on their Covid Treatment Trials of Opaganib. RDHL had better FAST TRACK that treatment toward FDA approval to contain pneumonia in those fighting for their lives , especially if the current COVID-19 vaccines prove less effective on the mutations of Covid popping up in South Africa and Japan via Brazil.
Will it tank? I do not know. But I am betting 1,000 shares long that it does not tank.
** 12/31/20 PR:
“...Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks. The Company will provide the data for peer review when available.
"We are pleased with these encouraging top-line results from our exploratory Phase 2 study which confirm opaganib's safety and demonstrate promising signals of activity when treating patients with COVID-19 and who require oxygen support. These preliminary results support our ongoing global Phase 2/3 study in severe COVID-19 pneumonia, which is expected to read out in Q1/2021. We continue to work diligently to compile a robust data set to support potential filing of global emergency use applications," said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill...”
Well that is what I was asking. Don’t know the answer.
Was wondering why that old company would/could want to buy by millions of dollars of RDHL stock AT A HIGHER PRICE than Red Hill would trade at if it tanks big time. Why not just wait for it to tank and get it cheaper?
It seems like RDHL is sitting on likely positive news due out shortly (mentioned in last PR)** on their Covid Treatment Trials of Opaganib. RDHL had better FAST TRACK that treatment toward FDA approval to contain pneumonia in those fighting for their lives , especially if the current COVID-19 vaccines prove less effective on the mutations of Covid popping up in South Africa and Japan via Brazil.
Will it tank? I do not know. But I am betting 1,000 shares long that it does not tank.
** 12/31/20 PR:
“...Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks. The Company will provide the data for peer review when available.
"We are pleased with these encouraging top-line results from our exploratory Phase 2 study which confirm opaganib's safety and demonstrate promising signals of activity when treating patients with COVID-19 and who require oxygen support. These preliminary results support our ongoing global Phase 2/3 study in severe COVID-19 pneumonia, which is expected to read out in Q1/2021. We continue to work diligently to compile a robust data set to support potential filing of global emergency use applications," said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill...”
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:07 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 05:14:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 02:00:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:01:02 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2026 12:00:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/27/2026 12:00:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/22/2026 09:06:45 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 01/22/2026 09:04:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2026 01:56:03 PM
- RedHill Biopharma Shares Jump on Progress Toward Treating GLP-1 Side Effects • IH Market News • 01/05/2026 02:59:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2026 12:02:00 PM
- RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects • PR Newswire (US) • 01/05/2026 12:00:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 12/31/2025 10:09:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/31/2025 09:58:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 12:00:39 PM
